Vol 27, No 2 (2022)
Letter to the Editor
Published online: 2022-02-04

open access

Page views 4447
Article views/downloads 241
Get Citation

Connect on Social Media

Connect on Social Media

Stereotactic radiotherapy of oligometastatic disease: a new paradigm for a curative approach

Marco Krengli12, Cynthia Aristei3, Simona Borghesi4, Stefano Maria Magrini5
Rep Pract Oncol Radiother 2022;27(2):376-378.

Abstract

No abstract available

Article available in PDF format

View PDF Download PDF file

References

  1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995; 13(1): 8–10.
  2. Dilling TJ, Hoffe SE. Stereotactic body radiation therapy: transcending the conventional to improve outcomes. Cancer Control. 2008; 15(2): 104–111.
  3. Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011; 8(6): 378–382.
  4. Lievens Y, Guckenberger M, Gomez D, et al. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiother Oncol. 2020; 148: 157–166.
  5. Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020; 21(1): e18–e28.
  6. Palma DA, Bauman GS, Rodrigues GB. Beyond Oligometastases. Int J Radiat Oncol Biol Phys. 2020; 107(2): 253–256.
  7. Sutera P, Clump DA, Kalash R, et al. Initial Results of a Multicenter Phase 2 Trial of Stereotactic Ablative Radiation Therapy for Oligometastatic Cancer. Int J Radiat Oncol Biol Phys. 2019; 103(1): 116–122.
  8. Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019; 393(10185): 2051–2058.
  9. Chalkidou A, Macmillan T, Grzeda M, et al. Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study. Lancet Oncol. 2021; 22(1): 98–106.
  10. Foster CC, Pitroda SP, Weichselbaum RR. Staging the Metastatic Spectrum Through Integration of Clinical and Molecular Features. J Clin Oncol. 2019; 37(15): 1270–1276.
  11. Annede P, Chargari C. [Oligometastases and oligoprogressions: Concepts and natural history]. Cancer Radiother. 2019; 23(6–7): 475–481.



Reports of Practical Oncology and Radiotherapy